The pharma will acquire Araris Biotech to gain access to three preclinical ADCs and a linking technology Araris claims is superior to existing platforms.

NEW YORK, NY / ACCESS Newswire / March 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Highlights,Institutional investments in Biohaven Ltd. have shown recent increases.,The company focuses on developing ...

NEW YORK, NY / ACCESS Newswire / March 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

We recently published a list of 12 Stocks with Heavy Insider Buying in 2025. In this article, we are going to take a look at ...

Stock analysts at Cantor Fitzgerald reduced their FY2025 earnings estimates for shares of Biohaven in a research note issued on Tuesday, March 4th. Cantor Fitzgerald analyst C. Duncan now expects that ...

Highlights,Institutional firms have modified their holdings in Biohaven Ltd., contributing to shifts in stock ...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Biohaven fair value estimate is US$28.35 With US$31.37 ...

Principal Financial Group Inc. raised its holdings in Biohaven Ltd. (NYSE:BHVN – Free Report) by 4.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 77,387 ...

Robert Lenz is leaving the brain drug developer to “pursue other interests.” Elsewhere, Atara is cutting half of its staff ...

NEW YORK, March 4, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd ("Biohaven" or the "Company") (NYSE: BHVN). Such investors are advised to contact ...

NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd. ("Biohaven Ltd.") (NYSE:BHVN) concerning possible ...